{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:33:27Z","timestamp":1793457207885,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL141445"],"award-info":[{"award-number":["K23HL141445"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"crossref","award":["Medical Student Summer Research Program"],"award-info":[{"award-number":["Medical Student Summer Research Program"]}],"id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40615-022-01252-3","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:02:42Z","timestamp":1643738562000},"page":"644-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of Race\/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA"],"prefix":"10.1007","volume":"10","author":[{"given":"Mingqian","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana E.","family":"Pezzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mohamedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Kansagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"1252_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.24433","volume":"91","author":"MA Gertz","year":"2016","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91:947\u201356.","journal-title":"Am J Hematol"},{"key":"1252_CR2","first-page":"2017","volume":"1\u201312","author":"G Merlini","year":"2017","unstructured":"Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017;1\u201312:2017.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/ejh.13472","volume":"105","author":"A Schulman","year":"2020","unstructured":"Schulman A, Connors LH, Weinberg J, et al. Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020;105:495\u2013501.","journal-title":"Eur J Haematol"},{"key":"1252_CR4","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641\u201354.","journal-title":"Lancet"},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989\u201395.","journal-title":"J Clin Oncol"},{"key":"1252_CR6","doi-asserted-by":"crossref","unstructured":"Sanchorawala V, Boccadoro M, Gertz M, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid:1\u20137, 2021","DOI":"10.1080\/13506129.2021.2002841"},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2:1046\u201353.","journal-title":"Blood Adv"},{"key":"1252_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/13506129.2019.1640672","volume":"26","author":"A Staron","year":"2019","unstructured":"Staron A, Connors LH, Ruberg FL, et al. A new era of amyloidosis: the trends at a major US referral centre. Amyloid. 2019;26:192\u20136.","journal-title":"Amyloid"},{"key":"1252_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/leu.2009.134","volume":"23","author":"O Landgren","year":"2009","unstructured":"Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691\u20137.","journal-title":"Leukemia"},{"key":"1252_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","volume":"3","author":"KM Alexander","year":"2018","unstructured":"Alexander KM, Orav J, Singh A, et al. Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis. Jama Cardiol. 2018;3:865\u201370.","journal-title":"Jama Cardiol"},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jama.2021.2104","volume":"325","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL, et al. The reporting of race and ethnicity in medical and science journals: comments invited. Jama. 2021;325:1049\u201352.","journal-title":"Jama"},{"key":"1252_CR12","unstructured":"Group WoS: Journal Citation Report 2020, Clarivate, 2020"},{"key":"1252_CR13","unstructured":"Bureau USC: About Race, 2021"},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-020-00385-0","volume":"10","author":"A Staron","year":"2020","unstructured":"Staron A, Connors LH, Zheng L, et al. Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020;10:118.","journal-title":"Blood Cancer J"},{"key":"1252_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-021-00466-8","volume":"11","author":"A D'Souza","year":"2021","unstructured":"D\u2019Souza A, Pezzin L, Laud P, et al. Racial disparities in patients diagnosed with light chain (AL) amyloidosis. Blood Cancer J. 2021;11:72.","journal-title":"Blood Cancer J"},{"key":"1252_CR16","unstructured":"RIghts USDotIOoC: Standards for maintaining, collecting, and presenting federal data on race and ethnicity, 1997"},{"key":"1252_CR17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/cncr.10785","volume":"95","author":"GM Swanson","year":"2002","unstructured":"Swanson GM, Bailar JC 3rd. Selection and description of cancer clinical trials participants\u2013science or happenstance? Cancer. 2002;95:950\u20139.","journal-title":"Cancer"},{"key":"1252_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-009-0411-4","volume":"118","author":"KW Mitchell","year":"2009","unstructured":"Mitchell KW, Carey LA, Peppercorn J. Reporting of race and ethnicity in breast cancer research: room for improvement. Breast Cancer Res Treat. 2009;118:511\u20137.","journal-title":"Breast Cancer Res Treat"},{"key":"1252_CR19","doi-asserted-by":"crossref","unstructured":"Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. Jama Oncol 5:e191870, 2019","DOI":"10.1001\/jamaoncol.2019.1870"},{"key":"1252_CR20","unstructured":"Vince RA, Jr., Eyrich NW, Mahal BA, et al. Reporting of racial health disparities research: are we making progress? J Clin Oncol:Jco2101780, 2021"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-022-01252-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-022-01252-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-022-01252-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T18:13:32Z","timestamp":1678126412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-022-01252-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40615-022-01252-3","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ML, LP, MA have no conflicts to reports. AK reports the following: Advisory Board:Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, Takeda, AD reports the following: Research funding: Caelum, Prothena, Sanofi, Takeda, TeneoBio, Advisory Board: Pfizer, Bristol Myers Squibb, Consultant: Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}